Our Dysferlin Research Institute
The Dysferlin Research Institute is the branch of the Jain Foundation that directs and manages all aspects of its research funding program. We fund basic and translational research focused on understanding and curing dysferlinopathy, including the biological function of dysferlin and its role in muscle, the pathology of dysferlin deficiency, and therapeutic strategies to restoring dysferlin expression or compensating for its absence. Our funded projects are the result of an interactive development process described in our unique funding model. We also develop tools and resources to aid dysferlin research, as well as organize and sponsor an annual conference for scientists and clinicians studying dysferlin.
The Dysferlin Research Institute branch of the Jain Foundation has evolved into a leading player in the dysferlin field, as described in this message from the Jain Foundation president.
Please visit the pages below for more information from the Dysferlin Research Institute:
Dysferlin Background
Detailed scientific background on the dysferlinopathies and the current state of dysferlin research, including a list of relevant publications in the field.
Research Tools
Description of research tools generated by the Jain Foundation, such as dysferlin cDNA constructs, animal models, and antibodies, as well as a link to the Jain Foundation research tool sharing network.
Funded Projects
Descriptions of all current and past research and diagnostic projects funded by the Jain Foundation.
Conferences
Detailed information on past and upcoming Dysferlin Conferences sponsored by the Jain Foundation.
Funding Statistics
Graphical representations of Jain Foundation research funding statistics over time.
Apply For Funding
Detailed instructions on how to apply for, or renew, funding from the Jain Foundation.
Funding Model
Description of the Jain Foundation's unique funding model and interactive approach to managing funded research projects.
Progress Metrics
Proposed metrics to measure the Jain Foundation's effectiveness and the scientific community's progress towards developing a therapy for dysferlinopathy.
